MUTAGEN SENSITIVITY IN PATIENTS WITH HEAD AND NECK CANCERS - A BIOLOGIC MARKER FOR RISK OF MULTIPLE PRIMARY MALIGNANCIES
MUTAGEN SENSITIVITY IN PATIENTS WITH HEAD AND NECK CANCERS - A BIOLOGIC MARKER FOR RISK OF MULTIPLE PRIMARY MALIGNANCIES
复制标题
DOI：
10.1093/jnci/82.22.1773
复制
发表时间：
1990-11-21
影响因子：
10.3
通讯作者：
HSU, TC
中科院分区：
文献类型：
--
作者：
SCHANTZ, SP;SPITZ, MR;HSU, TC
对84例头颈癌患者进行了体外诱变剂敏感性评估，并对其进行了纵向随访，以观察其发生多原发癌的情况。我们通过在体外将淋巴细胞暴露于博莱霉素，并对博莱霉素诱导的每个细胞的染色体断裂进行量化，来评估诱变剂的敏感性。诱变剂超敏患者，即那些每个细胞表达大于1.0 Break的患者，比不敏感的患者更有可能患上多原发癌(.(相对风险=4.4；95%可信区间=1.2、15.8)。这种关系与年龄、性别、部位和首次原发癌症以及吸烟或酒精暴露的治疗无关。对博莱霉素引起的染色体损伤的敏感性是头颈癌患者对多种原发恶性肿瘤遗传易感性的指标。
Eighty-four patients with head and neck cancers were evaluated for in vitro sensitivity to mutagens and then followed longitudinally for development of multiple primary malignancies. We assessed mutagen sensitivity by exposing lymphocytes to bleomycin in vitro and quantitating the bleomycin-induced chromosomal breaks per cell. The mutagen-hypersensitive patients, ie, those who expressed greater than 1.0 break per cell, were significantly more likely to develop multiple primary cancers than were patients who were less sensitive (.ltoreq. 1.0 break per cell) (relative risk = 4.4; 95% confidence limits = 1.2, 15.8). This relationship was independent of age, sex, site, and treatment of first primary cancer and tobacco or alcohol exposures. Sensitivity to bleomycin-induced chromosomal damage serves as an indicator of genetic susceptibility to multiple primary malignancies in patients with head and neck cancers.